ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
190,600
-10,400 (-5.17%)
At close: Dec 5, 2025
566.43%
Market Cap 10.51T
Revenue (ttm) 88.44B
Net Income (ttm) -28.65B
Shares Out 55.13M
EPS (ttm) -575.91
PE Ratio n/a
Forward PE 949.41
Dividend n/a
Ex-Dividend Date n/a
Volume 2,635,907
Average Volume 1,827,381
Open 210,000
Previous Close 201,000
Day's Range 187,900 - 220,000
52-Week Range 26,350 - 220,000
Beta 0.53
RSI 69.34
Earnings Date Nov 10, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.